Literature DB >> 16193249

A multicentre prospective collection of newly diagnosed glioblastoma patients in Lombardia, Italy.

A Salmaggi1, M Riva, A Silvani, R Merli, G Tomei, L Lorusso, A Russo, E Marchioni, F Imbesi.   

Abstract

The objective was to set the basis for a prospective, multicentre data collection on newly diagnosed adult glioblastoma patients diagnosed in Lombardia by means of a common database used by neurological and neurosurgical units of various hospitals, providing epidemiological, therapy and follow-up data. All adult patients with a newly diagnosed glioblastoma in 9 Lombardia hospitals from 31 March 2003 to 31 March 2004 were followed prospectively by a form elaborated by the Lombardia Neuro-oncology Group. Demographic data were recorded, as well as symptoms at onset, entity of tumour resection, post-surgical Karnofsky Performance Score, radio- and chemotherapy, presence/absence of venous thrombosis, type of antiepileptic treatment, time to tumour progression and survival time (ST). One hundred and thirty-four newly diagnosed glioblastoma patients were enrolled during the first year of the study. Male/female ratio was 1.6:1. Median age was 61 years. The most common single sign/symptom at disease onset included seizures, followed by mood/cognition changes and headache. In 71 patients, the tumour involved 1 brain lobe at diagnosis. Twenty-five patients underwent biopsy, 51 partial removal and 51 grossly total removal. At analysis of predictive value on ST, grossly total resection and chemotherapy were significantly associated with a longer ST. Age younger than 50 showed a trend to predictive value. A very high proportion of patients were treated with antiepileptic drugs, even in the absence of seizures. Median ST was 12 months in our cohort. Data in newly diagnosed glioblastoma patients in Lombardia are in line with other case series reported in other populations.

Entities:  

Mesh:

Year:  2005        PMID: 16193249     DOI: 10.1007/s10072-005-0465-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  5 in total

1.  Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

Authors:  T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

2.  Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience.

Authors:  Andrea Salmaggi; Antonio Silvani; Rossella Merli; Manuela Caroli; Giustino Tomei; Annamaria Russo; Maurizio Riva; Enrico Marchioni; Francesca Imbesi
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

Review 3.  CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.

Authors:  Roberto Würth; Adriana Bajetto; Jeffrey K Harrison; Federica Barbieri; Tullio Florio
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

4.  Anatomical features of primary brain tumors affect seizure risk and semiology.

Authors:  Kevin Akeret; Carlo Serra; Omar Rafi; Victor E Staartjes; Jorn Fierstra; David Bellut; Nicolai Maldaner; Lukas L Imbach; Fabian Wolpert; Rositsa Poryazova; Luca Regli; Niklaus Krayenbühl
Journal:  Neuroimage Clin       Date:  2019-01-25       Impact factor: 4.881

5.  Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma.

Authors:  Joshua D Palmer; Gordon Chavez; Wesley Furnback; Po-Ya Chuang; Bruce Wang; Christina Proescholdt; Chao-Hsiun Tang
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.